Liquidia Technologies Inc (LQDA)vsTakeda Pharmaceutical Co Ltd ADR (TAK)
LQDA
Liquidia Technologies Inc
$75.49
-1.10%
HEALTHCARE · Cap: $6.33B
TAK
Takeda Pharmaceutical Co Ltd ADR
$15.47
+0.97%
HEALTHCARE · Cap: $49.39B
Smart Verdict
WallStSmart Research — data-driven comparison
Takeda Pharmaceutical Co Ltd ADR generates 1564033% more annual revenue ($4.51T vs $288.06M). LQDA leads profitability with a 7.7% profit margin vs -3.4%. TAK earns a higher WallStSmart Score of 57/100 (C).
LQDA
Buy54
out of 100
Grade: C-
TAK
Buy57
out of 100
Grade: C
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 46.3%
Revenue surging 4159.0% year-over-year
Every $100 of equity generates 28 in profit
Growing faster than its price suggests
Reasonable price relative to book value
Earnings expanding 330.2% YoY
Areas to Watch
0.0% earnings growth
7.7% margin — thin
Elevated debt levels
Premium valuation, high expectations priced in
3.9% revenue growth
ROE of 2.5% — below average capital efficiency
Negative free cash flow — burning cash
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : LQDA
The strongest argument for LQDA centers on Operating Margin, Revenue Growth, Return on Equity. Revenue growth of 4159.0% demonstrates continued momentum.
Bull Case : TAK
The strongest argument for TAK centers on PEG Ratio, Price/Book, EPS Growth. PEG of 0.40 suggests the stock is reasonably priced for its growth.
Bear Case : LQDA
The primary concerns for LQDA are EPS Growth, Profit Margin, Debt/Equity. A P/E of 419.0x leaves little room for execution misses. Debt-to-equity of 1.70 is elevated, increasing financial risk.
Bear Case : TAK
The primary concerns for TAK are Revenue Growth, Return on Equity, Free Cash Flow.
Key Dynamics to Monitor
LQDA profiles as a hypergrowth stock while TAK is a turnaround play — different risk/reward profiles.
LQDA carries more volatility with a beta of 0.59 — expect wider price swings.
LQDA is growing revenue faster at 4159.0% — sustainability is the question.
LQDA generates stronger free cash flow (50M), providing more financial flexibility.
Bottom Line
TAK scores higher overall (57/100 vs 54/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Liquidia Technologies Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and markets various products for the unmet needs of patients in the United States. The company is headquartered in Morrisville, North Carolina.
Takeda Pharmaceutical Co Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Takeda Pharmaceutical Company Limited is engaged in the research, development, manufacture and marketing of pharmaceuticals, over-the-counter drugs and quasi-drug consumer products, and other health care products. The company is headquartered in Tokyo, Japan.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?